ADMET profile of selected favipiravir derivativesa (ref. 72).
| Comp. | MW | log P | DH/AH | log S | Intestinal absorption (%) | CNS | Tox. (LD50) |
|---|---|---|---|---|---|---|---|
| 1-F | 157.10 | -0.99 | 2/3 | −1.45 | 86.80 | −3.06 | 1.92 |
| 1-Cl | 173.56 | −0.48 | 2/3 | −1.94 | 87.00 | −3.07 | 2.12 |
| 1-Br | 218.01 | −0.37 | 2/3 | −2.03 | 86.95 | −3.06 | 2.13 |
| 2-F | 157.10 | −0.58 | 2/4 | −1.88 | 86.04 | −3.12 | 1.52 |
| 2-Cl | 173.56 | −0.06 | 2/4 | −2.29 | 86.59 | −3.11 | 1.8 |
| 2-Br | 218.01 | 0.04 | 2/4 | −2.36 | 86.53 | −3.11 | 1.81 |
Comp = compounds favipiravir derivatives. ADME parameters: MW = molecular weight, DH = number of H bonds donors, AB = number of H bonds acceptors, log P = partition coefficient, log S = predicted aqueous solubility, CNS = predicted central nervous system, Tox = oral rat acute toxicity (mol kg−1).